Ultra-Short-Course Seasonal Allergy Vaccine (Pollinex® Quattro)
▴ This novel ultra-short-course seasonal allergy vaccine, containing glutaraldehyde-modified allergens and the adjuvants 3-deacylated monophosphoryl lipid A (MPL®) and L-tyrosine, requires a preseasonal course of only four injections to be effective in the treatment of seasonal allergic rhinitis.
▴ In patients with seasonal allergic rhinitis and/or allergic asthma, a four-injection vaccination course with either the grass pollen or tree pollen allergy vaccine significantly reduced skin prick sensitivity reactions, significantly elevated allergen-specific IgG levels and significantly reduced the seasonally induced boost of IgE.
▴ Preseasonal vaccination of adult patients with either grass pollen or tree pollen allergy vaccine significantly reduced the median combined symptom/ medication score compared with placebo.
▴ Similarly, preseasonal vaccination of children and adolescents with allergies to grass pollen or tree pollen significantly reduced the global symptom and medication use scores compared with the previous pollen season.
▴ Postmarketing surveillance indicated that after a course of vaccination, 82% of patients experienced reduced symptoms and 62% reduced their rescue medication use compared with the previous season.
▴ The allergy vaccine was generally well tolerated. Local reactions, mainly injection-site redness and swelling, were more common than systemic reactions. There were no serious adverse events.
KeywordsAllergic Rhinitis Pollen Season Grass Pollen Tree Pollen Seasonal Allergic Rhinitis
- 10.Clay M, Urban E. Specific immunotherapy using pollen aller-goids adjuvanted with monophosphoryl lipid A over a three year period shows good efficacy and increased tolerability [abstract no. 4]. Clin Exp Allergy 2005; 35: 1411. Plus poster presented at the Annual Conference of the British Society for Allergy and Clinical Immunology; 2005 Jul 18–21; Loughborough, UKGoogle Scholar
- 12.Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003 Sep; 33(9): 1198–208PubMedCrossRefGoogle Scholar
- 15.Drachenberg KJ, Heinzkill M, Urban E. Short-term immunotherapy with tree pollen allergoids and the adjuvant monophosphoryl lipid A: results from a multicentre, placebocontrolled, randomised, double-blind study [in German]. Al-lergologie 2002; 25(9): 466–74Google Scholar
- 16.Röver AC, Reimann S, Zuberbier T, et al. Immunophenotypic characterization of peripheral B cells during short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A. J Invest Allergol Clin Immunol 2002; 12(4): 227–34Google Scholar
- 18.Stuck BA, Schneider-Gene S, Schäfer D, et al. Short-term preseasonal immunotherapy with birch pollen allergoid plus monophosphoryl lipid A (MPL): influence of cytokine production of peripheral T cells in patients with allergic rhinitis. Allergy Clin Immunol Int - J World Allergy Org 2004; 16(2): 60–4CrossRefGoogle Scholar
- 19.von Baehr V, Hermes A, von Baehr R, et al. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Thl-adjuvanted allergy vaccine. J Investig Allergol Clin Immunol 2005; 15(4): 234–41Google Scholar
- 20.Drachenberg KJ, Pröll S, Urban E, et al. Short-term immunotherapy using an allergy vaccine adjuvanted with monophosphoryl lipid A: a post-marketing surveillance study. Int Rev Allergol Clin Immunol 2002; 8(4): 219–23Google Scholar